DecImmune Therapeutics

DecImmune Therapeutics, Inc.Formed in 2001 and headquartered in Boston, US, DecImmune Therapeutics, Inc. develops innovative therapies targeting immune responses. In April 2013, the company was acquired by DSM Pharmaceutical Products.DecImmune specializes in the development and commercialization of innovative therapeutic solutions targeting immune-mediated diseases. The company’s core offerings include a range of monoclonal antibody products designed to modulate immune responses, which are particularly relevant in the treatment of autoimmune disorders and certain types of cancer. These therapies aim to enhance the efficacy of immune function while minimizing adverse effects, addressing significant unmet medical needs within the healthcare sector. DecImmune serves a diverse client base that includes healthcare providers, research institutions, and pharmaceutical companies across key geographical markets, including North America, Europe, and Asia-Pacific.DecImmune generates revenue primarily through a business-to-business (B2B) model, engaging in partnerships with pharmaceutical firms and healthcare organizations for the distribution of its therapeutic products. The company’s transaction structure often involves licensing agreements and collaborative research partnerships, allowing clients access to proprietary technologies and drug candidates. Revenue streams may also include royalties from product sales and milestone payments associated with successful clinical trials. Specific pricing plans are aligned with the complexity and development stage of their offerings, particularly their flagship monoclonal antibodies, which may be priced according to the therapeutic value they provide in clinical settings.25 mn obtained in April 2013 to support the development of new monoclonal antibodies and expand its market reach, targeting North America, Europe, and Asia-Pacific by 2015.

1. Series A

   Oct 5, 2006

   Amount

   $2.1M

   Investors

   Locked